Phase I Trial of Intraperitoneal Nab-Paclitaxel (Abraxane) in the Treatment of Advanced Malignancies Primarily Confined to the Peritoneal Cavity.
Phase of Trial: Phase I
Latest Information Update: 23 Jan 2018
At a glance
- Drugs Paclitaxel (Primary)
- Indications Peritoneal cancer
- Focus Adverse reactions
- 17 Jan 2018 Status changed from active, no longer recruiting to completed.
- 16 Dec 2016 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.
- 16 Dec 2016 Planned primary completion date changed from 1 Feb 2017 to 1 Feb 2018.